AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Metadoze-IPR 850 Tablet SR

Prescription Icon
Prescription Required

Marketer

Biocon

Salt Composition

Metformin (850mg)

Overview Metadoze-IPR 850 Tablet SR

Metformin SR 850mg tablets are prescribed for managing type 2 diabetes, effectively regulating blood glucose and mitigating the risk of associated complications. This medication also aids in the treatment of Polycystic Ovary Syndrome (PCOS) in women. For optimal absorption and to minimize gastrointestinal upset, it's recommended to take this medication with food, consistently at the same time daily. Discontinuation should only occur under medical supervision. Maintaining a healthy lifestyle, including adhering to a prescribed diet and exercise regimen, significantly contributes to diabetes management and complements the medication's effects. Commonly reported side effects include diarrhea, nausea, vomiting, gas, fatigue, indigestion, abdominal discomfort, headache, and decreased appetite. Hypoglycemia (low blood sugar) may occur, particularly when combined with other diabetes medications, alcohol consumption, or missed meals; regular blood sugar monitoring is crucial. Prior to commencing treatment, individuals with kidney, liver, or heart conditions, as well as pregnant or breastfeeding women, should consult their physician. Renal function assessment is standard before initiating therapy. Excessive alcohol should be avoided due to a heightened risk of side effects.

Uses of Metadoze-IPR 850 Tablet SR

Management of type 2 diabetes and polycystic ovary syndrome

Major Benefits of Metadoze-IPR 850 Tablet SR:

Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Metadoze-IPR 850 Tablet SR with a meal.

Common Side effects of Metadoze-IPR 850 Tablet SR:

  • Diarrhea
  • Headache
  • Vomiting
  • Nausea
  • Flatulence
  • Abdominal discomfort
  • Weakness

How to use Metadoze-IPR 850 Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Metadoze-IPR 850 Tablet SR whole; avoid chewing, crushing, or breaking it. Administer this medicine with a meal.

How Metadoze-IPR 850 Tablet SR works:

Metformin extended-release 850mg tablets are a biguanide-class antidiabetic drug. Their mechanism of action involves reducing hepatic glucose output, slowing intestinal glucose absorption, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Metadoze-IPR 850 Tablet SR and alcohol is not advised due to safety concerns.

PregnancyPregnancySAFE IF PRESCRIBED

The extended-release Metadoze-IPR 850mg tablet is typically deemed safe for use during gestation. Preclinical trials in animals have revealed minimal or no negative consequences for fetal development; nevertheless, data from human trials are scarce.

Breast feedingBreast feedingCAUTION

Extended-release Metadoze-IPR 850 mg tablets require careful consideration during lactation. Mothers should discontinue breastfeeding for the duration of treatment and until the medication is fully cleared from their system.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Metadoze-IPR 850 SR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Metadoze-IPR 850 SR tablets are contraindicated in individuals with severe kidney disease.

LiverLiverUNSAFE

Extended-release Metadoze-IPR 850mg tablets are contraindicated in individuals with hepatic impairment and should be omitted. Physician consultation is advised.

What if you forget to take Metadoze-IPR 850 Tablet SR :

Should you forget to take your Metadoze-IPR 850 Tablet SR, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Metadoze-IPR 850 Tablet SR

LabelValue
Pharmaceutical Category Guanidine derivative
Potential for Dependence None.
Type of Medication Medication for diabetes

FAQs on Metadoze-IPR 850 Tablet SR

Individuals with type 2 diabetes exhibit impaired responsiveness to endogenous insulin. Consequently, blood glucose levels elevate. Metadoze-IPR 850 Tablet SR employs a multifaceted approach to lower hyperglycemia. This involves reducing hepatic glucose production, diminishing intestinal glucose absorption postprandially, and enhancing insulin sensitivity in peripheral tissues. This combined action facilitates improved glucose uptake from the bloodstream and augments the body's natural insulin response.
Individuals using Metadoze-IPR 850 SR tablets have experienced weight reduction, particularly those classified as overweight or obese. This weight loss effect may also be observed in overweight and obese patients predisposed to diabetes. Furthermore, weight loss is possible in patients with insulin resistance or sensitivity. However, self-initiating this medication for weight management is discouraged; a physician's consultation is essential.
Metadoze-IPR 850 SR tablets are among the initial treatments prescribed for hyperglycemia. This medication manages blood glucose by enhancing the body's insulin response, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral antidiabetic agents, solo administration of Metadoze-IPR 850 SR tablets infrequently leads to hypoglycemia due to its inhibition of excess insulin release. Beyond glycemic control, this medication also aids in weight management.
Extended-release Metadoze-IPR 850mg tablets typically do not induce drowsiness and are generally well-received. Infrequently, though, Metadoze-IPR 850mg tablets may lead to sleep disturbances or insomnia. Drowsiness can be a symptom of a severe adverse reaction known as lactic acidosis, especially if renal function is impaired. Consult your physician if fatigue or somnolence develops during Metadoze-IPR 850mg tablet use.
Administer Metadoze-IPR 850 Tablet SR with or following a meal. The tablets should be swallowed whole with water; do not crush or chew them. For once-daily prescriptions, consume the tablet in the morning with breakfast. If two tablets are prescribed, take one with breakfast and the other with dinner. For three daily doses, distribute them with breakfast, lunch, and dinner. Ingesting Metadoze-IPR 850 Tablet SR with food mitigates potential gastrointestinal issues such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to their own insulin. This results in elevated blood glucose levels. Metadoze-IPR 850 Tablet SR works through multiple mechanisms to lower these elevated blood sugar levels. It reduces glucose synthesis in the liver, diminishes glucose absorption from the intestines following meals, and enhances the insulin sensitivity of tissues and muscles. This combined action facilitates improved glucose uptake from the bloodstream and improves the body's natural insulin response.
Individuals using Metadoze-IPR 850 SR tablets have experienced weight reduction, particularly those classified as overweight or obese. This effect may also be observed, albeit less significantly, in overweight or obese individuals predisposed to diabetes. Furthermore, weight loss can occur in patients with insulin sensitivity or resistance. However, self-prescribing this medication for weight management is strongly discouraged; physician consultation is essential before commencing treatment.
Metadoze-IPR 850 SR tablets are a primary treatment option for individuals with elevated blood glucose. This medication manages blood sugar by enhancing the body's insulin response, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral hypoglycemic agents, solo administration of Metadoze-IPR 850 SR tablets infrequently results in hypoglycemia due to its inhibition of excessive insulin secretion. Beyond its efficacy in glycemic control, this medication also aids in weight management.
Extended-release Metadoze-IPR 850mg tablets generally don't induce drowsiness and are typically well-received. Infrequently, however, they may lead to sleep disturbances or insomnia. Drowsiness can be a symptom of a severe adverse reaction known as lactic acidosis, especially if kidney function is impaired. Consult your physician if fatigue or sleepiness develops during Metadoze-IPR 850mg tablet treatment.
Administer Metadoze-IPR 850 Tablet SR with or following a meal. The tablets should be swallowed whole with water; do not crush or chew them. For once-daily prescriptions, take the tablet in the morning with breakfast. For twice-daily prescriptions, take one tablet with breakfast and the other with dinner. If three doses are prescribed, administer one with breakfast, one with lunch, and one with dinner. Consuming Metadoze-IPR 850 Tablet SR with food mitigates potential gastrointestinal issues such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to their endogenous insulin. This results in elevated blood glucose concentrations. Metadoze-IPR 850 Tablet SR works through multiple mechanisms to lower these elevated blood sugar levels. It reduces hepatic glucose production, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in tissues and organs. This facilitates improved glucose uptake from the bloodstream. Furthermore, it promotes a more effective response to naturally produced insulin.
Individuals overweight or obese have experienced weight reduction while using Metadoze-IPR 850 SR tablets. This weight loss effect may also be observed in overweight or obese individuals pre-disposed to diabetes. Similarly, those with insulin sensitivity or resistance might lose weight. However, self-medicating with this drug for weight management is strongly discouraged; always seek professional medical advice.
Metadoze-IPR 850 SR tablets are among the initial treatments prescribed for hyperglycemia. This medication aids in blood glucose regulation by enhancing the body's insulin response, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral antidiabetic agents, solo administration of Metadoze-IPR 850 SR tablets infrequently results in hypoglycemia due to its inhibition of excessive insulin secretion. Beyond glycemic control, this medication also assists in managing weight increase.
Extended-release Metadoze-IPR 850 mg tablets typically do not induce drowsiness and are generally well-received. Infrequently, though, Metadoze-IPR 850 mg tablets may lead to sleep disturbances or insomnia. Somnolence can be a symptom of a severe adverse reaction known as lactic acidosis, especially in individuals with impaired kidney function. Seek medical attention if fatigue or sleepiness develops during Metadoze-IPR 850 mg tablet use.
Administer Metadoze-IPR 850 Tablet SR with or following a meal. The tablets should be swallowed whole with water; avoid crushing or chewing. For once-daily prescriptions, morning ingestion with breakfast is recommended. Twice-daily regimens should involve one tablet in the morning and one in the evening, with meals. If three doses are prescribed, take the third with lunch. Consuming Metadoze-IPR 850 Tablet SR during meals mitigates potential gastrointestinal distress, including indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Metadoze-IPR 850 Tablet S...
33
MRP 40
17% off